irritable-bowel-syndrome

Documents about irritable-bowel-syndrome

• Efficacy and Safety of DT01 Tablets in Patients With Irritable Bowel Syndrome With Diarrhea#854744ClinicalTrials.gov
• The FAIS-Trial: Faecal Microbiota Transplantation (FMT) in Adolescents With Refractory Irritable Bowel Syndrome (IBS)#863626ClinicalTrials.gov
• Fecal Microbiota Transplantation to Relieve Symptoms of Irritable Bowel Syndrome With Constipation#903545ClinicalTrials.gov
• Vivatlac in Irritable Bowel Syndrome II (ViIBS2)#982547ClinicalTrials.gov
• Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome#873779ClinicalTrials.gov
• Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut#812600ClinicalTrials.gov
• Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study#826879ClinicalTrials.gov
• A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c#827867ClinicalTrials.gov
• Exercise and Vagus Nerve Stimulation in IBS#876247ClinicalTrials.gov
• Manipulation of Visceral Sensitivity and Immune System in IBS#904161ClinicalTrials.gov
• The Prevalence and Risk Factors of Irritable Bowel Syndrome Among Adults#969178ClinicalTrials.gov
• Clinical Efficacy and Safety of Jingfang Granules in Treating Diarrhea-Predominant Irritable Bowel Syndrome With Cold-Dampness Disturbing Spleen Syndrome#913627ClinicalTrials.gov
• Exclude or Expose in Irritable Bowel Syndrome: What Works for Whom and How?#834271ClinicalTrials.gov
• Maastricht IBS Cohort#827370ClinicalTrials.gov
• A systematic review of associations between functional connectivity, mood and cognition in patients with irritable bowel syndrome#5510Europe PMC
• Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre?#847322ClinicalTrials.gov
• The Effect of Neu-P11 on Symptoms in Patients With D-IBS#851900ClinicalTrials.gov
• NCWS or IBS/FD in Relatives of CD Patients#870671ClinicalTrials.gov
• Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)#877582ClinicalTrials.gov
• Lactobacillus LB as Treatment for Irritable Bowel Syndrome With Predominance of Diarrhea (IBS-D)#886065ClinicalTrials.gov
• Brachyspira and Intestinal Allergy-like Immune Reactions in Patients With Irritable Bowel Syndrome (IBS)#908213ClinicalTrials.gov
• Mesotherapy Treatment of Irritable Bowel Syndrome#834125ClinicalTrials.gov
• Brain Changes Underlying Irritable Bowel Syndrome Symptom Improvement in Response to Mindfulness-Based Stress Reduction#67606Europe PMC
• Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression#858239ClinicalTrials.gov
• Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome#884748ClinicalTrials.gov
• Prevalence of Gluten Sensitivity in Irritable Bowel Syndrome: The First Study in Paediatrics.#892469ClinicalTrials.gov
• Donor Selection for Faecal Microbiota Transplantation in Irritable Bowel Syndrome#910798ClinicalTrials.gov
• Clinical Trial Examining Effects of Monosodium Glutamate (MSG) on Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM)#915459ClinicalTrials.gov
• Efficacy of a Probiotic Blend to Reduce Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome#969053ClinicalTrials.gov
• Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use#1010476ClinicalTrials.gov
• Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome#846906ClinicalTrials.gov
• Brain Imaging, Heart Rate Variability and Serum Fatty Acid in Subjects With Irritable Bowel Syndrome#886704ClinicalTrials.gov
• Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders#838058ClinicalTrials.gov
• Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS)#982695ClinicalTrials.gov
• Rifaximin on Visceral Hypersensitivity#160403ClinicalTrials.gov
• EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth#902592ClinicalTrials.gov
• Pain Relief In Irritable Bowel Syndrome#801818ClinicalTrials.gov
• Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)#832394ClinicalTrials.gov
• Transcranial Magnetic Stimulation and Pharmacologic/Probiotic Interventions for Diarrhea-Predominant IBS#834942ClinicalTrials.gov
• The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and Irritable Bowel Syndrome (IBS) Patients#877305ClinicalTrials.gov
• Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome#901110ClinicalTrials.gov
• Probiotics for the Treatment of Irritable Bowel Syndrome in Celiac Patients#993728ClinicalTrials.gov
• Ileocecal Sphincter Reflex by Cecal Distension During Colonoscopy#853277ClinicalTrials.gov
• Table 1_Multi-omics mendelian randomization integrating GWAS and eQTL data revealed potential drug target for irritable bowel syndrome.xlsx#197958Figshare
• Table 2_Multi-omics mendelian randomization integrating GWAS and eQTL data revealed potential drug target for irritable bowel syndrome.xlsx#197959Figshare
• Table 3_Multi-omics mendelian randomization integrating GWAS and eQTL data revealed potential drug target for irritable bowel syndrome.xlsx#197960Figshare
• Table 7_Multi-omics mendelian randomization integrating GWAS and eQTL data revealed potential drug target for irritable bowel syndrome.xlsx#197961Figshare
• Table 8_Multi-omics mendelian randomization integrating GWAS and eQTL data revealed potential drug target for irritable bowel syndrome.xlsx#197962Figshare
• Table 4_Multi-omics mendelian randomization integrating GWAS and eQTL data revealed potential drug target for irritable bowel syndrome.xlsx#197963Figshare
• Table 5_Multi-omics mendelian randomization integrating GWAS and eQTL data revealed potential drug target for irritable bowel syndrome.xlsx#197964Figshare